What is CAR T-Cell Therapy?

One of the most promising cell-based immunotherapy cancer treatments is CAR T-cell therapy (Chimeric Antigen Receptor T-cell therapy). The treatment involves:

  • Removing immune system T-cells from the blood stream
  • Shipping T-cell product to a manufacturing laboratory
  • Genetically engineer (reprogram) T-cells to produce special receptors on their surface called Chimeric Antigen Receptors, or CARs. This enables the T-cells to better recognize and kill cancer cells.
  • Expand T-cells to make billions of new enhanced T-cells
  • Infuse CAR T-cell product back to the patient to target and kill malignant cancer cells

Please review our NSH Immunotherapy Program pamphlet for additional information.

Future FDA approved CAR T-cell disease indications will become available soon. Current and future clinical research studies involving the use of CAR T-cell therapy in leukemia, lymphoma and myeloma will be ongoing.